Objectives To determine the effects of low-dose transdermal hormone therapy (HT) on systolic (SBP) and diastolic (DBP) blood pressure (BP) evaluated by 24-h ambulatory blood pressure monitoring (ABPM) in hypertensive postmenopausal women.
Objectives To determine the effects of low-dose transdermal hormone therapy (HT) on systolic (SBP) and diastolic (DBP) blood pressure (BP) evaluated by 24-h ambulatory blood pressure monitoring (ABPM) in hypertensive postmenopausal women.
Methods The study was conducted on 24 hypertensive postmenopausal women aged, on average, 54 years and under treatment with enalapril maleate (10-20 mg/day) combined or not with hydrochlorothiazide (25 mg/day). Thirteen women used a transdermal adhesive containing estradiol and norethisterone (25 and 125 lg active substance/day, respectively) and 11 did not receive HT. ABPM, lipid profile, and climacteric symptoms were evaluated before and 3 and 6 months after treatment.
Results After 3 and 6 months of follow-up, there was a statistically significant reduction of the Blatt-Kupperman menopausal index in the treated group (19.6 ± 8.3 vs. 9.6 ± 5.9 vs. 9.7 ± 7.0; P = 0.01). No significant difference in any of the ABPM variables (areas under the systolic and diastolic curves, mean SBP and DBP, SBP and DBP loads and wakefulness-sleep variation) or in the lipid profile was observed between or within groups at the three time points studied. 
Conclusion

Introduction
Arterial hypertension (AH) is a disease occurring at high frequency in the menopause, which, by being one of the main risk factors for cardiovascular disease, requires careful attention. Particularly important is the occurrence of climacteric symptoms in hypertensive women as there is now some reluctance in prescribing hormone therapy (HT) to these patients. In fact, despite the proven beneficial effects of estrogens on the cardiovascular apparatus obtained in experimental studies, their use began to be strongly questioned after the publication of the results of the Women's Health Initiative study, which showed that the cardiovascular risks exceeded the benefits of treatment [1] . Although the effects of HT on the cardiovascular apparatus are still controversial, it is not possible to deny a therapeutic option for the relief of symptoms, when present, in hypertensive women.
The data about the effects of HT in hypertensive menopausal women are discordant [2] [3] [4] [5] [6] . These studies differ in some aspects such as route of administration, dose, and type of estrogen and progestogen used. The diverse methods used in the various studies can also definitely interfere with the results and their interpretation. The traditional technique of office blood pressure (BP) measurement has limitations and may not be adequate for a precise evaluation of the effect of HT on BP. Twenty-four-hour ambulatory BP monitoring (ABPM) is a more valid method for the evaluation of BP behavior by permitting BP evaluation during wakefulness and sleep, in addition to eliminating interfering factors such as the 'white coat' effect [7] .
The variations in BP detected by ABPM are more frequently associated with AH complications compared with office measurements [7] . The evaluation of the circadian pattern of BP permits the detection of the occurrence of the physiological decline during sleep. It has been demonstrated that the reduction of BP during sleep compared with the wakefulness period is a good prognostic marker associated with a lesser extent of future involvement of target organs such as hypertrophy of the left ventricle, microalbuminuria, and brain lesions [8] [9] [10] . Moreover, studies have shown consistent correlations between morbidity, mortality, and BP measurements obtained by ABPM [11, 12] . These observations confirm the importance of 24-h ABPM.
Studies using 24-h ABPM to evaluate the effects of HT on BP in hypertensive women have used the mean of the values obtained for the interpretation of the results. Analysis of the area under the curve (AUC) for systolic BP (SBP) and diastolic BP (DBP) is a new parameter that has been developed for the interpretation of ABPM, proving to be strongly correlated with mean 24-h SBP and DBP [13] . The limitations reported in the literature regarding the BP loads (BPL), particularly for values close to 100% [14] , or even regarding 24-h mean values [15] , have not been identified in the AUC. The correlations of the AUC with the left ventricle mass index were as consistent as those obtained with mean BP and the AUC presented a good correlation with commonly used parameters such as mean 24-h value and BPL [13] .
In view of the high incidence of AH in postmenopausal women and the fact that many of these women present climacteric symptoms that require treatment, it is of great clinical interest to obtain a definitive clarification of the effects of HT on BP, especially in women with AH, as this is an important cardiovascular risk factor. The advent of low-dose HT as a new therapeutic option in the menopause, as well as the possibility of its application by the transdermal route, has brought new perspectives for HT in hypertensive women.
Thus, the objective of this study was to determine the effect of low-dose transdermal HT on SBP and DBP evaluated by 24-h ABPM by the analysis of the AUC for BP and of the habitual ABPM parameters in postmenopausal hypertensive women. Our intention was to determine whether low-dose transdermal HT could be used safely by hypertensive women with climacteric symptoms.
Methods
Twenty-four postmenopausal women with mild-to-moderate AH under treatment with enalapril maleate (10-20 mg/day), in combination or not with hydrochlorothiazide (25 mg/day), were included in this study. The patients were divided into two groups: (i) 13 patients submitted to HT with a combination of transdermal estrogen and progestogen, and (ii) 11 patients not submitted to HT. The type and dosages of the antihypertensive agents remained unaltered during the 6-month follow-up.
Inclusion criteria were age between 45 and 60 years; last spontaneous menstrual cycle more than 12 consecutive months before inclusion in the study; serum concentration of follicle-stimulating hormone of more than 40 IU/ ml; climacteric symptoms and/or loss of bone mass; stages 1-2 AH (S 1 -S 2 ) according to the criteria of the 'V Brazilian Directives for Arterial Hypertension' [16] , identified in untreated patients, and patients under antihypertensive treatment with controlled BP. All patients gave written informed consent to participate.
Exclusion criteria were earlier or current thromboembolic disease, severe cardiac arrhythmia, coronary artery disease, cerebrovascular disease; any malignant neoplasia except successfully treated basal cell skin cancer; abnormal genital bleeding of undetermined cause; diabetes mellitus; hepatic or cholestatic diseases; severe depression; blood clotting disorders; renal insufficiency; endocrinopathies except controlled thyroid disease; smoking; alcoholism; drug addiction; obesity (body mass index > 30 kg/m 2 ), and use of HT during the last 3 months before inclusion in the study.
The selected patients were submitted to full clinical evaluation consisting of anamnesis and detailed physical examination. The climacteric symptoms were evaluated according to the menopausal index of Blatt-Kupperman [17] . Complementary exams included the Papanicolaou test, fasting glycemia, serum creatinine and potassium, routine urinalysis, determination of plasma folliclestimulating hormone and thyroid-stimulating hormone, transvaginal ultrasonography, mammography, and bone densitometry. The patients were assigned to receive HT, except those with contraindications to this therapy, who were included in the control group.
The group submitted to HT used a transdermal system containing 17-b-estradiol and norethisterone acetate releasing 25 and 125 mg of the active substances per day, respectively.
Twenty-four-hour ABPM was performed with a portable automatic instrument (SpaceLabs, model 90207, Issaquah, Washington, USA), programmed to determine BP at 15-min intervals during wakefulness and at 20-min intervals during sleep. The results were interpreted on the basis of analysis of the area under the systolic curve (AUSC) and diastolic curve (AUDC) for the values obtained in the 24-h period, during wakefulness and sleep [13] . Mean SBP and DBP values and systolic (SBPL) and diastolic BP loads (DBPL) were also evaluated during the 24-h period, wakefulness and sleep, in addition to the wakefulness-sleep variation. ABPM was performed during the basal period and after 3 and 6 months of followup. The exams were considered to be satisfactory when there were at least 21 valid recordings, 14 of them during wakefulness and seven during sleep.
In the evaluation of the wakefulness-sleep variation, the individuals were classified as dippers for SBP and DBP when the physiological decline during sleep was 10-20%, as nondippers when the decline was less 10%, as extreme dippers when the decline was 20% or more, and as inverted dippers when the decline was less than 0% [18] .
Total cholesterol, HDL-cholesterol, and triglyceride concentrations were determined with a kit from Roche Diagnostics (São Paulo, Brazil) using a colorimetric and enzymatic method. LDL-cholesterol concentrations were determined by the formula of Friedwald [LDL = CT -(HDL + TGC/5)]. Friedwald's formula is more reliable when transdermal estrogen is used compared with oral estrogen, which can increase the triglyceride levels [19] .
The study was designed to detect a difference of 5 mmHg in BP with a power of 80 and 5% significance level (two-tailed test).
The nonparametric Kruskal-Wallis test for dependent variables was used for statistical comparison of the groups at baseline using the software R with the Kruskal test command. A mixed effect model for dependent variables was used for group comparison at the three time points and during the two patient states (wakefulness and sleep) using the SAS 9.0 software (SAS Institute INC, Cary, North Carolina, USA) and the PROC MIXED feature.
This study was approved by the Research Ethics Committee of the University Hospital, Faculty of Medicine of Ribeirão Preto, University of São Paulo. Table 1 presents the clinical characteristics, biochemical evaluation, and hormone measurements for the patients studied, obtained at the time of the initial evaluation. No significant difference between groups in any of the parameters evaluated was present.
Results
Comparison of the lipid profile variables, the BlattKupperman menopausal index, the waist-hip ratio, and the body mass index at the different treatment time points showed that only the menopausal index differed significantly from baseline at 3 and 6 months in the treated group (19.61 ± 8.34 vs. 9.69 ± 5.90 vs. 9.76 ± 7.03; P = 0.01) ( Table 2) .
Comparison of the ABPM variables (SBP, DBP, SBPL, DBPL, AUSC, and AUDC in 24-h, wakefulness and sleep) showed no significant difference between or within groups at the three time points. A tendency toward a reduction of SBPL and DBPL was, however, observed after 6 months of follow-up in the treated group (Table 3) .
Although AUSC and AUDC constantly showed lower values in the treated group, no significant differences were observed between or within groups at the three time points. A negative correlation was, however, observed between the AUSC and time of follow-up in the treated group (r = -0.65) (Fig. 1) . Values are expressed as mean ± SD. BMI, body mass index; DBP, diastolic blood pressure; FSH, follicle-stimulating hormone; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TCG, triglycerides; TSH, thyroid-stimulating hormone; W/H ratio, waist/hip ratio. Values are expressed as mean ± SD. *P = 0.01 compared to baseline. BMI, body mass index; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; m, months; TC, total cholesterol; TCG, triglycerides; W/H ratio, waist/hip ratio.
Hormone therapy and hypertension de Carvalho et al. 279
In the treated group, there were 46% (n = 6) SBP dippers and 38% (n = 5) DBP dippers at baseline, with these values being 46% (n = 6) and 69% (n = 9), respectively, at the end of follow-up. In the control group there were 27% (n = 3) SBP and DBP dippers at baseline, with these values being 54% (n = 6) and 45% (n = 5), respectively, at the end of follow-up. Figure 2 shows the wakefulnesssleep variation in SBP and DBP in the treated and control groups at baseline and after 3 and 6 months of follow-up.
Discussion
Climacteric symptoms are associated with a significant impairment of quality of life during menopause and are particularly important by currently being the main indication for HT. Although several therapeutic options Table 3 Systolic blood pressure, diastolic blood pressure, systolic blood pressure load, diastolic blood pressure load, area under the systolic curve and area under the diastolic curve for the treated group and the control group at baseline and after 3 and 6 months of follow-up Values are expressed as mean ± SD. AUDC, area under the diastolic curve; AUSC, area under the systolic curve; BMI, body mass index; DBP, diastolic blood pressure; DBPL, diastolic blood pressure load; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; m, months; SBP, systolic blood pressure; SBPL, systolic blood pressure load; TC, total cholesterol; TCG, triglycerides; W/H ratio, waist/hip ratio. are available, HT continues to be the most effective for the relief of these symptoms [20] .
AH is one of the main risk factors for cardiovascular disease [21] . As its incidence increases significantly after the fifth decade of life, a period coinciding with the postmenopausal phase, hypoestrogenism has been suggested to be involved in the onset of this disease [22] .
At present, the major question is about the ideal time when HT should be started to obtain the greatest benefits. An early institution of HT when advanced atherosclerosis is not yet present may inhibit the progression of this disease and have a cardioprotective effect. When HT is started late, as is the case for secondary prevention, atherosclerosis is already in an advanced stage and HT may induce cardiovascular events [23] .
Studies conducted on hypertensive menopausal women have reported discordant results. These studies differ in some aspects such as route of administration and type of estrogen and progestogen used. However, in all of these studies, except a recently published one [6] , conventional doses of hormonal medication were used.
Some risks of HT, particularly the increased occurrence of stroke and venous thromboembolism, are related to the hormone dose used [24, 25] . Thus, the proposal of reducing the hormone doses compared with those that were being conventionally used is progressively attracting interest and gaining space in clinical practice.
The improvement of the menopausal index of BlattKupperman observed in the present patients confirmed the efficacy of low-dose transdermal HT in improving the climacteric symptoms. As HT is currently indicated mainly to relieve symptoms, we wish to emphasize the importance of this result, which has also been observed by others [26] .
After 6 months of low-dose transdermal HT the patients did not show any statistically significant changes in total cholesterol, HDL-cholesterol, LDL-cholesterol or triglycerides, although a tendency toward a reduction of total cholesterol and LDL-cholesterol was observed. The absence of significant results in the lipid profile could be explained by the small number of patients, as the study was not designed to detect changes in this outcome.
In addition to evaluating climacteric symptoms and the lipid profile, in this study we intended to determine whether HT could be used by patients with controlled AH without compromising their clinical status.
All studies that used 24-h ABPM as the method for evaluation of BP behavior used the mean of the values obtained to interpret the results. In this respect, this study is the first in the literature to use low-dose transdermal HT in hypertensive women and the AUC of the values obtained [13] as a new parameter for the interpretation of the results of ABPM. Analysis of the AUC of SBP and DBP was used because it shows a good correlation with previously used parameters such as mean 24-h SBP and DBP and BPL, but without some of the limitations of the latter [14, 15] .
In our study, postmenopausal women with stages 1-2 AH using antihypertensive treatment did not show changes in BP evaluated by 24-h ABPM after the use of low-dose combined transdermal HT for a period of 6 months. In studies using ABPM in hypertensive women, oral and transdermal HT showed a neutral or decreasing effect on BP [2] [3] [4] [5] [6] . Most of the studies that showed a decreasing Wakefulness-sleep variation in systolic blood pressure (SBP) and diastolic blood pressure (DBP) in the treated and control groups at baseline and after 3 and 6 months of follow-up.
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effect on BP used standard doses or even high doses of estrogens [27] . On the basis of our results, we may assume that the plasma estrogen concentrations obtained with low-dose HT were not sufficient to exert a decreasing effect on BP, or that the action of progestogen may have canceled the eventual beneficial effect of estrogen.
Some authors propose that women on HT can be divided into responders and nonresponders when the effects of HT on endogenous nitric oxide levels are evaluated [5] . Individual ability to reestablish estrogen expression may explain this phenomenon. On this basis, hypertensive women with endothelial dysfunction may have a lower capacity of reestablishing the estrogen receptors in response to estrogen therapy, thus presenting lower beneficial effects in response to this therapy [28] .
Some studies suggest a particular action of HT on sleep BP [29, 30] , an important observation as sleep SBP was considered to be the best predictor of a major cardiovascular event (stroke, acute myocardial infarction, and death) in the Systolic Hypertension in Europe Study and in the Ohasama Study [31, 32] . In this study we did not observe changes in the wakefulness-sleep variation after HT, a fact that led us to conclude that this treatment did not alter the circadian rhythm of BP in the patients evaluated. This suggests that HT at the doses and route of administration used has no negative effects on BP behavior in postmenopausal women with controlled stages 1-2 AH.
Analysis of AUC showed no change, although we observed a tendency to reduce 24-h AUSC in treated group. We also observed a tendency to reduce BPL after HT. Although the clinical interpretation of these parameters has not been well established, an association has been observed between AUC and BPL and injury to target organs [13, 33] .
These results have immediate practical effects when we consider the large number of hypertensive women who require HT for relief of climacteric symptoms but to whom these medications are not prescribed in view of possible cardiovascular risks. It is clear that the time of treatment used here was too short for a more precise analysis of long-term cardiovascular risks. Furthermore, our study was not randomized. Our objective was to demonstrate a difference of 5 mmHg between the groups. However, the study failed to demonstrate such a difference as the number of patients was relatively small. We had many dropouts because of the low compliance of patients with HT. The results, however, indicate that HT does not interfere with BP in women with stages 1-2 AH, as is also the case for normotensive patients [34] , suggesting the possibility of their use for the treatment of climacteric symptoms in controlled hypertensive women. If some increase in cardiovascular risk should exist for these patients, this would not be because of a worsening of the hypertension, but rather to other factors that need to be studied.
